United States End-Stage Kidney Disease (ESKD) Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Dialysis, Kidney Transplantation, Medications & Supportive Care), By Modality (In-Center Dialysis, Home Dialysis), By End-User (Hospitals & Clinics, Dialysis Centers, Homecare Settings, Research & Academic Institutes, Others) and Forecasts, 2025-2033
USD 3800
United States End-Stage Kidney Disease (ESKD) Treatment Market Insights
The United States represents the largest segment within the North American ESKD treatment market, with growth propelled by a high incidence of diabetes and hypertension—two leading causes of kidney failure. According to the United States Renal Data System (USRDS), over 800,000 Americans live with ESKD, and this number is growing steadily each year.
A key driver is robust government support, such as Medicare coverage for dialysis and transplant services, which makes treatment more accessible. Additionally, the U.S. is at the forefront of technological advancements in dialysis equipment and artificial kidney research, backed by strong investment from both the private sector and federal agencies like the NIH.
However, the market faces notable restraints including organ shortages for transplantation and disparities in healthcare access, particularly in rural and underserved communities. High treatment costs continue to challenge patient affordability, even with insurance coverage.
Emerging trends include the adoption of home hemodialysis and telehealth services, as patient preference shifts toward flexible, personalized care. The integration of AI and predictive analytics is also gaining traction, improving diagnosis and treatment planning. Furthermore, pharmaceutical innovation is accelerating the development of novel drugs that slow CKD progression and delay the onset of ESKD.
Opportunity abounds in expanding home-based treatment solutions and implementing AI-powered diagnostics and monitoring systems. As healthcare policies increasingly favor cost-effective, patient-centric care, the U.S. market is expected to see a shift from hospital-based dialysis centers to at-home treatment setups.
TABLE - United States End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Treatment Type 2021-2033
| Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Hemodialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Peritoneal Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Kidney Transplantation | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Deceased Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Living Donor Transplant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Medications & Supportive Care | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Immunosuppressants | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Erythropoiesis-Stimulating Agents (ESA) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| - Phosphate Binders | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - United States End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By Modality 2021-2033
| Modality | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In-Center Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Home Dialysis | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - United States End-Stage Kidney Disease (ESKD) Treatment Market Size & Forecast By End-User 2021-2033
| End-User | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals & Clinics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Dialysis Centers | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Homecare Settings | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Research & Academic Institutes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Others | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
| Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
Report Benefits
- Develop business strategies by understanding the trends shaping and driving the Market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track sales in the global and country-specific Market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.